NXTSTIM
NXTSTIM is a San Diego-based medical device company that develops EcoAI, an FDA-cleared, AI-powered, non-invasive neuromodulation device with Remote Therapeutic Monitoring for chronic pain management, sold through licensed partner clinics and a growing Centers of Excellence network.
- Company typePrivate
- Founded2020
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NXTSTIM does
NXTSTIM is a San Diego-based medical device company founded in 2020 by Dr. Krishnan Chakravarthy that develops and commercializes EcoAI, an FDA 510(k)-cleared, AI-powered, non-invasive neuromodulation device for chronic pain management. The product is built around proprietary SmartWave waveform technology delivered through a small, wireless, rechargeable wearable paired with a mobile application and a clinician-facing dashboard. Dual sensors capture neural and EMG responses, and an AI module closes the loop by adjusting stimulation parameters in real time, with a published 75% accuracy for pain-response prediction in real-world studies. The system is designed for home use while feeding Remote Therapeutic Monitoring (RTM) data back to prescribing clinicians under HIPAA/HITECH compliance and a Business Associate Agreement framework.
The business sells EcoAI exclusively through a prescription-only channel: licensed partner clinics, a growing national Centers of Excellence network, and an internal in-house LPN/LVN care management team that handles onboarding, training, patient support, and RTM documentation. Revenue is generated through three streams: hardware sales of the EcoAI device and recurring gel-pad consumables, RTM services billed by clinics via CMS-aligned CPT codes (98975/98977/98980/98981), and professional services supporting clinic onboarding and billing. Reimbursement is enabled across Medicare, Medicaid (state-dependent), and major commercial payors including UnitedHealthcare. The go-to-market combines enterprise field sales into physician practices with patient-facing demand generation through the website, app stores, podcasts, conferences, and peer-reviewed publications such as the Journal of Pain Research.
NXTSTIM has scaled from its 2020 founding through an NIH SBIR Phase 1 grant in 2021 to 1,000+ patients by 2023 and 3,000+ cumulative patients in 2025, with a stated 180% growth rate in 2025. The installed base is supported by 24 months of real-world outcome data showing a 92% compliance rate at 18+ months, a 2.5-point average reduction on the numeric pain rating scale, and zero reported device-related adverse events. The company is privately held and founder-controlled, headquartered in San Diego, with an operating footprint primarily in the U.S. and selected international advocacy (e.g., AZ Delta Hospital in Belgium) but no disclosed venture funding to date.
NXTSTIM firmographics
Firmographics- Name
- NXTSTIM
- Legal name
- NXTSTIM, Inc.
- Website
- https://nxtstim.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NXTSTIM is a San Diego-based medical device company that develops EcoAI, an FDA-cleared, AI-powered, non-invasive neuromodulation device with Remote Therapeutic Monitoring for chronic pain management, sold through licensed partner clinics and a growing Centers of Excellence network.
- Ownership category
- akta.pro rank
NXTSTIM industry classification
Industry- Product category
- Neuromodulation Pain Management Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)
- akta.pro secondary industries
- Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms (HLALABAK), Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG), Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN) (HLALADAD)
Keywords
Where NXTSTIM is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NXTSTIM business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- EcoAI Device Sales: EcoAI device is sold to patients through licensed partner clinics. The device is a one-time purchase that includes reusable hardware with rechargeable battery. Pricing is determined in partnership with insurance coverage.
- Gel Pads (Consumables): Disposable gel pads are sold as consumable supplies. Available in multiple sizes for optimal skin contact. Regular reordering required for ongoing therapy.
- Remote Therapeutic Monitoring (RTM) Services: Clinics bill for RTM services using CPT codes 98975-98981. NXTSTIM provides documentation tools and billing support. CMS reimbursement rates: $19.73 (setup), $43.02/month (device supply), $50.14/month (monitoring), $39.14/month (add-on monitoring).
- Professional Services & Support: NXTSTIM provides onboarding, staff training, patient support, and RTM assistance as part of the clinic partnership. Optional billing support includes review of RTM data and preparation of billing reports.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | CPT 98975 - Device Setup (One-time) |
| Other | Monthly | CPT 98977 - Device Supply (Monthly) |
| Other | Monthly | CPT 98980 - RTM Monitoring & Interaction (Monthly) |
| Other | Monthly | CPT 98981 - RTM Add-on Monitoring (Monthly) |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels8 records
NXTSTIM product offering
Product offeringCore offering
NXTSTIM designs and manufactures EcoAI, an FDA-cleared, AI-powered, non-invasive neuromodulation wearable device for chronic pain management, paired with a clinician-facing Remote Therapeutic Monitoring (RTM) platform. The product is prescription-only and sold through a network of licensed partner clinics (Centers of Excellence), with companion mobile apps (iOS/Android), disposable gel pad consumables, and cloud-based clinician dashboards for monitoring and CMS-aligned billing.
Product overview
NXTSTIM offers a unified ecosystem centered on EcoAI, an FDA-approved AI-powered neurostimulation device for chronic pain management. The ecosystem includes the EcoAI device with proprietary SmartWave technology, NXTSTIM mobile app (iOS/Android) for device control and therapy tracking, EcoAI Gel Pads as disposable accessories, a Clinician Dashboard for healthcare provider oversight, and Remote Therapeutic Monitoring (RTM) capabilities. The system provides a closed-loop pain relief solution where EcoAI adapts stimulation in real-time based on neural response monitoring, with all data syncing to both patient app and clinician dashboard for continuous care optimization.
Differentiator
Problem solved
Functional benefit
Brands
- EcoAI: FDA-approved, AI-powered, non-invasive neuromodulation device with Remote Therapeutic Monitoring (RTM) for pain relief. Features SmartWave technology that blocks pain signals and activates natural pain-blocking systems.
- SmartWave
Products and services
- EcoAI Neuromodulation Device FDA-cleared, wireless, wearable neuromodulation device that uses proprietary SmartWave technology combined with AI-driven adaptive therapy to deliver non-invasive, drug-free pain relief for chronic pain conditions (neck, back, shoulders, knees, muscle/nerve-related). Sold by prescription through partner clinics.
- NXTSTIM Mobile App Companion mobile application for iOS and Android that pairs with the EcoAI device, allows patients to select therapy modes (Relax, Strengthen, Relieve), tracks sessions in a treatment diary, delivers personalized recommendations, and connects to the care team for remote adjustments.
- EcoAI Gel Pads Disposable electrode pads sold in multiple sizes to ensure optimal skin contact for the EcoAI device across different body regions. Consumable that requires regular reordering for ongoing therapy.
- Clinician Dashboard / Provider Portal Web-based portal for healthcare providers that surfaces real-time adherence, therapy sessions, NRS pain scores, and pain trends per patient, and supports RTM billing with automated superbills and compliance tracking aligned with CMS CPT codes 98975-98981.
- Care Coordination Program Service program in which NXTSTIM's in-house LPN and LVN care team provides ongoing monitoring, personalized check-ins, patient education, and care coordination for chronic pain patients using EcoAI.
Quantifiable outcome
- 92% patient compliance rate at 18+ months
- +6 more outcomes
Companies that use NXTSTIM
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles2 records
NXTSTIM technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
NXTSTIM partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Journal of Pain ResearchcorePeer-reviewed publication partnership. A narrative review was published examining how EcoAI integrates remote patient monitoring with AI-powered neuromodulation to deliver personalized, adaptive pain treatment.
- Weill Cornell MedicineminorDr. Jaspal Ricky Singh from Weill Cornell Medicine is featured as an EcoAI advocate, providing testimonial on the device's ability to shape long-term patient care with non-pharmacologic pain therapy.
- AZ Delta Hospital (Belgium)minorDr. Bart Billet, MD Anesthesiologist at AZ Delta Hospital in Roeselare, Belgium, provides testimonial on EcoAI as an innovative, affordable, and non-invasive pain therapy option.
- ASPN (American Society of Pain and Neuroscience)minorNXTSTIM exhibited at ASPN 2025 conference presenting real-world data from 1,200 EcoAI users showing lasting pain relief, strong adherence, and predictive insights.
- SamaCareminorKip Theno and Dr. Chakravarthy appeared on the SamaCare podcast discussing EcoAI and pain management innovation.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
NXTSTIM competitors and assessment
Company assessmentBroad incumbents
- Boston Scientific: Boston Scientific markets the WaveWriter Alpha and Precision spinal cord stimulation systems. It is a broad incumbent in chronic-pain neuromodulation and a natural strategic acquirer of emerging neuromodulation assets.
- Abbott: Abbott offers the Proclaim DRG and Infinity spinal cord stimulation systems for chronic pain. It is a broad incumbent in implantable neuromodulation whose adjacent capabilities and physician relationships compete for chronic-pain wallet share.
- Omron Healthcare: Omron sells consumer and clinical TENS/EMS devices (e.g., Avail) for pain management. It is a broad incumbent that competes with EcoAI on the lower-cost consumer TENS side and could move up-market.
- Medtronic: Medtronic is a global medtech incumbent with a large neuromodulation portfolio (spinal cord stimulation, deep brain stimulation, targeted drug delivery). It is a broad incumbent whose scale and R&D could pressure NXTSTIM in adjacent indications.
- Axonics: Axonics makes sacral and tibial neuromodulation systems for incontinence and overactive bladder. It is a broad incumbent in non-opioid neuromodulation with a similar miniaturized, patient-friendly device + clinician-monitor model.
Emerging players
- SPR Therapeutics: SPR Therapeutics makes the Sprint peripheral nerve stimulation system for acute and chronic pain. It is an emerging neuromodulation peer that, like NXTSTIM, targets non-opioid pain pathways but with a minimally invasive approach.
- Hinge Health: Hinge Health is a digital musculoskeletal care platform combining exercise therapy, coaching, and wearable sensors. It is an emerging player in the chronic-pain management space that overlaps with NXTSTIM on the digital-care and RTM delivery model.
- Cala Health: Cala Health makes Cala Trio, a wearable TENS device for essential tremor. It is an emerging non-invasive neuromodulation peer using a similar prescription-wearable + app + clinician oversight model, focused on a different indication.
Direct peers
- electroCore: electroCore makes gammaCore, a non-invasive vagus nerve stimulation (nVNS) device for migraine and cluster headache. It is a direct non-invasive neuromodulation peer with a similar FDA-cleared prescription hardware + app model.
- NeuroMetrix: NeuroMetrix makes Quell, an FDA-cleared wearable TENS device for chronic pain. It is the most direct competitor to NXTSTIM's EcoAI in the over-the-counter / prescription neuromodulation category for chronic musculoskeletal pain.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
NXTSTIM social profiles
Digital presenceNXTSTIM compliance and trust
Trust signalCompliance5 records
NXTSTIM financial estimates
Financial estimateRevenue estimate
Valuation estimate
NXTSTIM leadership team
Management profileNumber of profiles
Profiles8 records
NXTSTIM funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NXTSTIM M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NXTSTIM
What does NXTSTIM do?
NXTSTIM designs and manufactures EcoAI, an FDA-cleared, AI-powered, non-invasive neuromodulation wearable device for chronic pain management, paired with a clinician-facing Remote Therapeutic Monitoring (RTM) platform. The product is prescription-only and sold through a network of licensed partner clinics (Centers of Excellence), with companion mobile apps (iOS/Android), disposable gel pad consumables, and cloud-based clinician dashboards for monitoring and CMS-aligned billing.
Is NXTSTIM a public or private company?
NXTSTIM is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was NXTSTIM founded?
NXTSTIM was founded in 2020. It employs 11 to 50 people.
Where is NXTSTIM based?
NXTSTIM is headquartered in San Diego, United States, in the North America region.
How does NXTSTIM make money?
Four revenue lines are on record. EcoAI Device Sales are the primary driver. The others are gel Pads (Consumables), remote Therapeutic Monitoring (RTM) Services and professional Services & Support.
Who are NXTSTIM's main competitors?
Broad incumbents on record are Boston Scientific, Abbott, Omron Healthcare, Medtronic and Axonics. Emerging players are SPR Therapeutics, Hinge Health and Cala Health. Direct peers are electroCore and NeuroMetrix.
Does NXTSTIM have an API?
No public API is recorded for NXTSTIM.
What industry is NXTSTIM in?
NXTSTIM's product category is Neuromodulation Pain Management Devices. Its primary akta.pro industry code is HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables), with a secondary code of HLALABAK, Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms. Its NAICS code is 334510 and its SIC code is 3845.